A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants
Latest Information Update: 28 Feb 2020
At a glance
- Drugs Pesampator (Primary)
- Indications Cognition disorders
- Focus Pharmacokinetics
- Sponsors Biogen
Most Recent Events
- 23 Feb 2020 Status changed from recruiting to completed.
- 29 Oct 2019 Status changed from not yet recruiting to recruiting.
- 10 Sep 2019 New trial record